XML 28 R21.htm IDEA: XBRL DOCUMENT v3.25.1
CAPITAL STOCK
 9 Months Ended
Dec. 31, 2024
Equity [Abstract]  
CAPITAL STOCK

NOTE 12 – CAPITAL STOCK

Our authorized capital consists of 200,000,000 shares of common stock with a par value of $0.001 per share.

2017 Equity Incentive Plan

In October 2017, the Board of Directors approved the 2017 Equity Incentive Plan ("2017 Plan"). Our 2017 Plan initially permitted the issuance of equity-based instruments covering up to a total of 485,000 shares of common stock. The Board of Directors and our stockholders approved an increase of 4,515,000 shares in October 2020 an additional increase of 1,000,000 shares in March 2023, and an additional increase of 3,000,000 shares in February 2024, bringing the total shares issuable under the 2017 Plan to 9,000,000. As of December 31, 2024, there were 2,400,148 shares available to issue under the 2017 Plan.

Warrants

At December 31, 2024, outstanding and exercisable stock purchase warrants consisted of the following:

 

Number of
Shares

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average Life
Remaining
(Years)

 

Outstanding at March 31, 2024

 

 

1,808,830

 

 

$

2.04

 

 

 

1.18

 

Granted

 

-

 

 

-

 

 

-

 

Exercised

 

-

 

 

-

 

 

-

 

Forfeited or cancelled

 

 

(87,574

)

 

 

2.35

 

 

-

 

Outstanding at December 31, 2024

 

 

1,721,256

 

 

$

2.03

 

 

 

0.37

 

Exercisable at December 31, 2024

 

 

1,721,256

 

 

$

2.03

 

 

 

0.37

 

 

As of December 31, 2024, we had 1,721,256 warrants outstanding. Each warrant provides the holder the right to purchase up to one share of our Common Stock at a predetermined exercise price. The outstanding warrants consist of (1) warrants to purchase 100,000 shares of Common Stock at an exercise price of $0.01 per share until December 2026; (2) warrants to purchase 911 shares of Common Stock at an exercise price of $1.65 per share until April 2025; (3) warrants to purchase 1,234,034 shares of our Common Stock at an exercise price of $2.00 per share consisting of 1% of the warrants that expired on August 2024, and 99% until February 2026; and (4) warrants to purchase 386,311 shares of Common Stock at an exercise price of $2.63 until November 2025.

Options Granted

During the year ended March 31, 2023, we granted stock options (“Options”) to purchase 400,000 shares of our Common Stock to our Chief Executive Officer, of which (i) 100,000 Options vested on July 24, 2023, and (ii) 300,000 Options shall vest in equal quarterly installments of 25,000 over three years beginning on September 30, 2023. The Options shall (a) be exercisable at an exercise price per share equal to the closing market price of the Company’s common stock on the date of the grant, (b) have a term of ten years, and (c) be on such other terms as shall be determined by the Board of Directors (or the Compensation Committee of the Board of Directors) and set forth in a customary form of stock option agreement under the 2017 Plan. We recognized $27,330 and $101,953 in expense related to the Options for the three and nine months ended December 31, 2024, respectively.

The following is a summary of our stock option activity during the nine months ended December 31, 2024:

 

Number of Options

 

 

Weighted Average Exercise Price

 

 

Weighted Average Grant Date Fair Value

 

 

Weighted Average Remaining Life in Years

 

Outstanding, April 1, 2024

 

 

 

400,000

 

 

$

 

2.08

 

 

$

 

1.50

 

 

 

 

9.32

 

Granted

 

 

 

-

 

 

 

 

-

 

 

 

 

-

 

 

 

 

-

 

Exercised

 

 

 

-

 

 

 

 

-

 

 

 

 

-

 

 

 

 

-

 

Canceled/Forfeited

 

 

 

-

 

 

 

 

-

 

 

 

 

-

 

 

 

 

-

 

Outstanding, December 31, 2024

 

 

 

400,000

 

 

$

2.08

 

 

$

 

1.50

 

 

 

 

9.07

 

As of December 31, 2024, there was $70,710 of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average vesting period of approximately 1.50 years.

Stock Awards

A summary of stock award activity for the nine months ended December 31, 2024 is as follows:

 

 

Number of Shares

 

 

Weighted-Average Grant-Date Fair Value Per Share

 

Outstanding at April 1, 2024

 

 

1,540,524

 

 

$

 

2.93

 

Granted

 

 

482,500

 

 

 

 

1.77

 

Vested

 

 

(1,263,940

)

 

 

 

2.82

 

Forfeited

 

 

(250,000

)

 

 

 

2.32

 

Outstanding at December 31, 2024

 

 

509,084

 

 

$

 

2.40

 

 

As of December 31, 2024, there was $1,222,234 of unrecognized compensation expense related to unvested stock awards, which is expected to be recognized over a weighted-average period of approximately 1.91 years.